Sort   by:  
 Page size 
MetabolomicsLipid Droplet Inhibitors for Disrupting Lipid Accumulation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Excessive lipid droplet accumulation in hepatocytes drives the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), often leading to inflammation and fibrosis. As obesity and metabolic syndrome rise, MASLD has become a global concern, spurring research into effective trea...
2025-07-17 | MTBLS12359 | MetaboLights
MetabolomicsPenthorum chinense Pursh Ameliorates Metabolic Dysfunction-Associated Alcohol-Related Liver Disease through Gut Microbiota Modulation and Metabolic Remodeling
Metabolic dysfunction-associated alcohol-related liver disease (MetALD) is characterized by hepatic steatosis, oxidative stress, inflammation, and gut microbiota dysbiosis resulting from the coexistence of metabolic dysfunction and alcohol consumption. Penthorum chinense Pursh is a traditional edibl...
2026-06-10 | MTBLS14735 | MetaboLights
MetabolomicsIntestinal TM6SF2 Protects Against Metabolic Dysfunction-associated Steatohepatitis through the Gut-Liver Axis

Transmembrane-6 superfamily member 2 (TM6SF2) regulates hepatic fat metabolism and is closely associated with metabolic dysfunction-associated steatohepatitis (MASH). MASH involves genetic predisposition and gut microbiota alteration, yet the role of host-microbes interaction in disease developme...

2024-10-08 | MTBLS11004 | MetaboLights
MetabolomicsDysregulated high-density lipoprotein and low-density lipoprotein subfractions increase metabolic dysfunction-associated steatotic liver disease risk: A study of patients across body mass index categories

Background: To investigate biomarker differences among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) across body mass index (BMI) types, we analyzed clinical data from 2,013 subjects and serum samples from 402 patients. The clinical characteristic...

2026-02-05 | MTBLS13821 | MetaboLights
MetabolomicsFirst-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Diminished hepatocyte regeneration is a key feature of acute and chronic liver diseases and after extended liver resections, resulting in the inability to maintain or restore a sufficient functional liver mass. Therapies to restore hepatocyte regeneration are lacking, making liver transplantation...

2024-09-23 | MTBLS9434 | MetaboLights
MetabolomicsA comprehensive multiomic analysis reveals metabolic reprogramming underlying human Fontan-associated liver disease

BACKGROUND: Single ventricle congenital heart disease (SVCHD) is a severe form of cardiac malformation in which there is only one functional ventricle. The Fontan operation is the current standard of care for SVCHD. Almost all patients who have undergone the Fontan operation develop liver fibrosi...

2024-12-13 | MTBLS10782 | MetaboLights
MetabolomicsDeficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease
Non-alcoholic fatty liver is the most common liver disease worldwide. Here, we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver disease. Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2...
2018-01-25 | MTBLS600 | MetaboLights
MetabolomicsGenetic Ablation of Sfxn5 Induces Mitochondrial Dysfunction and Precipitates Lethal Metabolic Crisis in Mice
Mitochondrial disorders frequently manifest with life-threatening hepatic metabolic crises. Using a global Sfxn5-knockout mouse model, we investigated the systemic consequences of disrupting this mitochondrial inner-membrane transporter through integrated biochemical, metabolomic, histological, and ...
2026-05-30 | MTBLS14628 | MetaboLights
MetabolomicsA metabolite-augmented FIB-4 machine learning panel achieves superior liver fibrosis staging in chronic liver disease

Accurate, non-invasive liver fibrosis detection is essential for chronic liver disease management, particularly with rising metabolic dysfunction-associated liver disease (MASLD) and chronic hepatitis B (CHB). While the Fibrosis-4 (FIB-4) index is widely used, its performance for advanced fibrosi...

2026-03-03 | MTBLS13946 | MetaboLights
MetabolomicsX chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction

Statin drugs lower blood cholesterol levels for cardiovascular disease prevention. Women are more likely than men to experience adverse statin effects, particularly new-onset diabetes (NOD) and muscle weakness. Here we find that impaired glucose homeostasis and muscle weakness in statin-treated f...

2024-05-23 | MTBLS9677 | MetaboLights
Sort   by:  
 Page size